f-star is an antibody engineering company based in Vienna, Austria. The company develops improved therapeutic antibodies and antibody fragments based on its Modular Antibody Technology, which allows the introduction of additional binding sites into antibodies and antibody fragments by engineering the non-CDR loops of constant or variable domains. Using Modular Antibody Technology, antibody fragments with antibody functionality and long half life but much smaller size (Fcab(tm)) or full antibodies with additional functionality (mAb”) can be created.

The company was founded by a team of experienced antibody engineering and biotech executives. Seed-financed by Austrian government agencies and Atlas Venture in 2006, the company raised EUR 9.0m in a Series A financing round from Aescap Venture, Atlas Venture and Novo A/S in 2007. In total, the company has raised more than EUR 13m so far.

Speaker Profile

Eugen Stermetz, CFO

Eugen Stermetzis CFO of f-star. Eugen helped secure f-star's seed financing round in 2006 and joined the company as CFO and Managing Director in 2007.
Eugen previously served as CFO of biotech companies Fibrex Medical and Igeneon after working as a management consultant with The Boston Consulting Group. In the course of a number of venture capital financing rounds, Eugen has helped biotech companies raise more the USD 100m in total so far. He graduated from the University of St. Gallen, Switzerland with a lic.oec. HSG degree and holds a doctorate in business administration from the Vienna University of Economics and Business Administration.